A Rare Case of Empedobacter Brevis Cutaneous Infection Treated Successfully With Oral Sarecycline

Adjei, Susuana; Miller, Austinn C.; Temiz, Laurie A.; Tyring, Stephen K.

doi:10.36849/jdd.6628

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of protecting the human intestinal microbiota cannot be overstated, as more evidence emerges about the intersecting roles of a healthy microbiome and overall human health, and the fact that investigations into the long-term impacts of antibiotics on the human intestinal microbiota revealed even short courses of oral antibiotics can have profound effects 2–4 years later [ 8 , 36 ]. Importantly, narrow-spectrum activity does not necessarily mean complete inactivity against Gram-negative organisms; sarecycline can be effective against some Gram-negative bacteria not associated with the human gut microbiota, such as Empedobacter brevis [ 37 ].…”

Section: Introductionmentioning

confidence: 99%

Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology

Grada¹,

Ghannoum

Bunick

2022

Antibiotics

View full text Add to dashboard Cite

Tetracycline class antibiotics are widely used for multiple skin diseases, including acne vulgaris, acne rosacea, cutaneous infections, inflammatory dermatoses, and autoimmune blistering disorders. Concerns about antibiotic resistance and protecting the human/host microbiome beg the question whether broad-spectrum tetracyclines such as doxycycline and minocycline should be prescribed at such a high rate by dermatologists when a narrow-spectrum tetracycline derivative, sarecycline, exists. We evaluated the clinical effectiveness of oral sarecycline against cutaneous staphylococcal infections, eyelid stye, and mucous membrane pemphigoid to determine whether sarecycline is a viable option for clinicians to practice improved antibiotic stewardship. We observed significant improvement in staphylococcal infections and inflammatory dermatoses with courses of oral sarecycline as short as 9 days, with no reported adverse events. These clinical findings are consistent with in vitro microbiological data and anti-inflammatory properties of sarecycline. Our data provides a strong rationale for clinicians to use narrow-spectrum sarecycline rather than broad-spectrum tetracyclines as a first-line agent in treating staphylococcal skin infections and inflammatory skin diseases for which tetracyclines are currently commonly employed. Such advancement in the practice paradigm in dermatology will enhance antibiotic stewardship, reduce risk of antibiotic resistance, protect the human microbiome, and provide patients with precision medicine care.

show abstract

Section: Introductionmentioning

confidence: 99%